Adenovirus (Adv)-mediated gene transfer has recently gained new attention as a means to deliver genes for hematopoietic stem cell (HSC) or progenitor cell gene therapy. In the past, HSCs have been regarded as poor Adv targets, mainly because they lack the specific Adv receptors required for efficient and productive Adv infection. In addition, the nonintegrating nature of Adv has prevented its application to HSC and bone marrow transduction protocols where long-term expression is required. There is even controversy as to whether Adv can infect hematopoietic cells at all. In fact, the ability of Adv to infect epithelium-based targets and its inability to effectively transfect HSCs have been used in the development of eradication schemes that use Adv to preferentially infect and "purge" tumor cell-contaminating HSC grafts. However, there are data supporting the existence of productive Adv infections into HSCs. Such protocols involve the application of cytokine mixtures, high multiplicities of infection, long incubation periods, and more recently, immunological and genetic modifications to Adv itself to enable it to efficiently transfer genes into HSCs. This is a rapidly growing field, both in terms of techniques and applications. This review examines the two sides of the Adv/CD34 controversy as well as the current developments in this field. Cancer Gene Therapy (2000) 7, 816 -825
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ecause of the many diseases involving hematopoietic cells and the very well-developed technology of bone marrow (BM) transplantation, hematopoietic celldirected gene therapy has been a very actively pursued and rapidly developing field of study. 1 The major applications of this technology can be grouped into three categories. First, it can be used to replace a missing or damaged gene in congenital diseases affecting cells derived from hematopoietic stem cells (HSCs). Second, it can be used for chemoprotection during antitumor therapy by transferring a drug-resistance gene to normal HSCs. In fact, for many years the fundamental goal of research in this field was the incorporation of exogenous genes into the genome of HSCs. Third, it can be used as a means of intracellular vaccination. For example, it can be used to inhibit HIV infection or progression by transferring antiviral genes to HSCs or T-cell precursors.
Until 3 years ago, retroviral vectors were the predominant vehicle being studied for gene transfer to HSCs, mainly because retroviral cDNA integrates into the genome of the host cell. Many in vitro studies, primate studies, and clinical trials with retroviral vectors have been conducted. However, the results from these studies suggest that retroviral-mediated gene delivery to HSCs is inefficient. 2, 3 Other reports suggest efficient retroviralmediated gene delivery, but this delivery was accomplished only through the use of modified ex vivo transduction protocols or by highly technical infection methods. 4, 5 The mixed results with retroviral vectors have consequently led researchers to search for better gene delivery vehicles. Some other vectors tested include adeno-associated virus 6, 7 lentiviruses, 8 foamy viruses, 9 and nonviral lipid-based delivery vectors. 10 These vectors have shown promise, but each is also associated with specific problems and limitations.
Adenovirus (Adv) has become a more promising vehicle for transferring genes to HSCs for several reasons. One advantage of Adv is that it does not require dividing cells for infection, thus making the transduction to quiescent stem cells possible. The quiescent nature of stem cells makes retroviral transduction very difficult, and efforts to manipulate HSCs in culture to increase retroviral transduction efficiency (i.e., initiate cell cycle entry) require that the growth of progenitor cells be stimulated, which is associated with the rapid loss of pluripotentiality. Another advantage of Adv is that high titers (Ͼ10 10 plaque-forming units (pfu)/mL) can be generated, unlike with retroviral vectors, which are produced at relatively low titers (10 5 to 10 6 pfu/mL), thus making high multiplicities of infection (MOIs) easy to achieve. A further advantage of Adv compared with retroviruses is that random integration of retroviral cDNA into the host genome might initiate mutations of many host genes, with carcinogenesis a possible consequence. In contrast, Adv cannot induce the dysfunction of host genes because it does not integrate. Hence, because long-term integration and expression by retrovirus-mediated gene transfer into patient cells has not been achieved as expected, it seems that Adv could be a promising vector for HSC gene therapy. This potential is because of the development of new generation Adv and new transduction protocols. Protocols that can be tested include the Adv-mediated delivery of viral receptors into stem cells for subsequent transduction with integrating viruses, Adv-mediated cytokine gene transduction into malignant hematopoietic cells for the creation of genemodified leukemia vaccinations, and the administration of Adv-delivered anti-apoptotic genes to prevent cell death during cryopreservation (Table 1) .
ADV TRANSDUCTION PATHWAY
Adv vectors have been used to transduce a wide range of cells, including epithelial cells, 10 endothelial cells, 11 muscle cells, 12 fibroblasts, 13,14 neuronal cells, 15 and several recently described HSCs. 16 -18 In target cells, Adv uses two distinct binding events to affect a productive infection. 19 First, Adv attaches to a host cell via the fiber knob region, which is the terminal end of its fiber proteins, 15, 19 to the cell surface fiber receptors recently identified as the Coxsackie virus-Adv receptor (CAR). 20, 21 This occurs for Adv serotype 2 and type 5. An additional report has identified binding to a host cell via the use of the ␣2 domain of the class I major histocompatibility complex for Adv type 5. 22 Such fiberto-fiber receptor-mediated Adv binding is the most prominent binding pathway that has been described. There is also some low-level fiber receptor-independent Adv binding in some nonepithelial cell models, 23 including some hematological cells. 24 After fiber-mediated attachment, viral internalization occurs through the Adv penton base proteins binding to cell surface ␣ V ␤ 3 and ␣ V ␤ 5 integrin receptors via the Arg-Gly-Asp (RGD) motif, which in turn triggers receptor-mediated endocytosis. 15,24 -27 This ␣ V integrin receptor-mediated virus internalization appears to be obligate.
A fiber receptor-independent binding pathway has been identified as well. The Adv type 2 penton base proteins bind to cell surface ␣ V integrin receptors of monocytic cells; however, ␣ V integrins are still required for the next step in infection, internalization of the virus into endosomes. 24 Once the virus is in an endosome, Adv disrupts the endosomal compartment and causes the release of the deconstructed Adv to the nuclear pore, where it injects its DNA into the nucleus. It is not clear whether both a receptor-binding event (fiber-to-fiber receptor) and the additional penton RGD integrin events are required for a productive Adv infection to occur, or whether just one event is sufficient to trigger internalization.
ADV TRANSDUCTION INTO HEMATOPOIETIC CELLS
Data not supporting Adv transduction Whether Adv can infect HSCs is controversial. Results of all early studies suggested that hematopoietic cells, especially HSCs or progenitor cells, are not transduced by Adv (Table 2) . For example, data presented by Wattel et al 28 showed that leukemic cell lines were not susceptible to Adv infection (MOI of 50:1; 2-hour incubation). Infection was only seen in the cell line K562. Clarke et al 29 showed that a 4-hour infection with an Adv containing a proapoptotic gene (MOI of 100:1) resulted in no detectable transfection of HSCs. Instead, the cells maintained their viability and retained their ability to reconstitute colonies in short-term 10-day proliferation assays. Seth et al 30 also reported that low-density BM cells were not infected by Adv. Using Scatchard plot analysis with radioactive Adv, they determined that epithelial cells contained Ͼ300-fold more Adv receptors per cell than low-density BM. They were unable to detect any significant Adv binding to low-density BM cells. Chen et al 31 determined that CD34 ϩ progenitor cells did not express the appropriate ␣ V , ␤ 3 , or ␤ 5 integrin subunits required for the efficient transduction of HSCs. In another experiment with reverse transcription-polymerase chain reaction (RT-PCR) to detect Adv-delivered gene products, they were unable to detect any positive transcript from 32 determined that HSCs were not targets of Adv infection; in addition, using marker enzyme assays, they showed that no apparent infection occurred during a short-term, 2-hour incubation period (MOI of 100:1). In addition, there was no reduction in the hematopoietic progenitor granulocyte-macrophage colony-forming unit (GM-CFU) of these transduced HSCs. Collectively, these data strongly suggest that hematopoietic cells are not efficient targets of Adv infection. These data also suggest that the natural targets of Adv (i.e., epithelial cells) are preferentially infected over hematopoietic cells. This understanding has in turn led investigators to develop an infection strategy whereby Adv infects target cells first during short-term exposure and leaves the nontarget (hematopoietic) cells untransduced, thereby creating a efficient targeting strategy based on the expression of Adv receptors.
Advantages of no infection
The ability of Adv to infect natural target cells quickly while sparing infection of nontarget cells has allowed the development of targeted infection protocols. Many investigators, including those in our group, have exploited this natural behavior of Adv to preferentially infect contaminating cancer cells cocultured in hematopoietic cell backgrounds. 33 In one example of this strategy, Clarke et al 29 demonstrated that an Adv vector expressing the proapoptotic gene BCL-X S would preferentially infect and kill 85-90% of primary breast cancer cells and multiple breast cancer cell lines, but not the hematopoietic cells, during a 4-hour incubation. They also observed that HSCs in human BM cocultured during the incubation period maintained their viability and retained their ability to reconstitute the BM. Seth et al 30 reported that compared with low-density BM cells, breast cancer cells are easily infected by recombinant Adv. Specifically, they compared the toxicity of Adp53 against breast cancer cells and BM CD34 cells in a mixture of MDA-MB-231 breast cancer cells and BM cells or CD34 ϩ cells from mobilized peripheral blood. They observed no colony formation of the breast cancer cells at an MOI of 10 pfu/cell (2-hour incubation). In contrast, there was no decline in CD34 ϩ colony formation in GM-CFU assays even when they increased the MOI to 100 pfu/cell. Wroblewski et al 32 further confirmed that Adv can purge contaminating malignant cells from HSC autographs. They used Adp53 to preferentially transduce MDA-MB-231 breast cancer cells but spare CD34 ϩ BM cells. They used an MOI of 10 pfu/cell and a 2-hour infection and observed no decline in the colony formation in GM-CFU assays. These results suggested that the CD34 ϩ cells were not infected. Chen et al 31 reported elimination of up to 6 log units of contaminating breast cancer cells (MCF-7, BT20) or other cancer cells, including A549 (lung cancer), DU145 (prostate cancer), and T98G (glioblastoma) cells at an MOI of 100 during a 2-hour infection by AdHSVtk followed by administration of ganciclovir. They observed no loss of the clonogenic potential of CD34 ϩ cells and no intoxication of HSCs. All of these findings suggest that solid tumor cells, such as breast cancer cells and neuroblastoma cells, can be preferentially transduced in coculture with hematopoietic cells or HSCs.
Data supporting Adv transduction
There are also contrasting data suggesting that Adv vectors do mediate gene transfer to CD34
ϩ HSCs (Table  2 ). For example, Watanabe et al 16 reported a transduction frequency of 24% and 30% of BM CD34 ϩ cells and BM mononuclear cells, respectively, that was achieved during a lengthy incubation period (24 -48 hours) at the high MOI of 500. In particular, they observed one case in which BM mononuclear cells showed a transduction frequency of 35.7% at an MOI of 50 during a 24-hour incubation period. However, alternative interpretations of some of the data of Watanabe et al 16 subsequently have suggested, in particular, that the fluorescenceactivated cell sorter (FACS) data indicate no Adv infection. 34 Nevertheless, Neering et al 17 confirmed the findings of Watanabe et al 16 regarding the transduction of hematopoietic cells by Adv with similar conditions. Specifically, they observed a transduction frequency of 45% in BM CD34
ϩ cells with an Adv-expressing alkaline phosphatase (AdMFG-AP) at an MOI of 500 during a 48-hour incubation. Additional data from Watanabe et al 35 demonstrated the ability of Adv to infect HSCs during long incubation periods (Ͼ24 hours) and at MOIs of Ͼ50. They also investigated the ability of growth factors (interleukin-3, granulocyte-macrophage colony-stimulating factor, and granulocyte colony-stimulating factor) to enhance transduction frequency and improve the maintenance of hematopoietic functions. In addition, work by Ahmed et al 36 demonstrated the ability of Adv to transduce purified CD34 ϩ cells at an MOI of 120 during a 48-hour incubation. Their data suggest that optimal infections occur after a 24-hour exposure. Frey et al 37 also recently reported efficient transduction of HSCs by an Adv carrying a green fluorescent protein reporter gene at an MOI of 100 -500 during a 24-hour incubation.
Possible immune consequences
While discussing transduction of hematopoietic cells by adenoviral vectors, it would be remiss to forget the possible immunological consequences and subsequent fate of these cells in an in vivo setting. Although not formally tested in hematopoietic cells, there are data that suggest that immune surveillance of Adv-infected cells could result in shortened expression of Adv-delivered genes, due mainly to immune clearance of these cells in vivo. 38 Although the current hypothesis for why Adv-infected cells are selectively cleared is being debated, experiments with Advs that are deleted in the E4 regions prolong gene expression by reducing immunological interactions. 39 Reconciliation of findings These findings raise the following question: How can Adv vectors both purge contaminating solid tumor cells in a hematopoietic cell background and not transduce hematopoietic cells, but also mediate efficient gene delivery to hematopoietic cells or HSCs? The answer may lie in the different infection conditions used. In all purging experiments conducted, the Adv infection was carried out at comparatively low MOIs (10 -100) with very short incubation times (2-4 hours). In contrast, the studies showing high gene transfer frequencies to hematopoietic cells all used high MOIs (100 -500) with longer incubation times (24 -48 hours), often in the presence of a cell cycle-stimulating cytokine cocktail. Although no results from studies of cytokine cocktails or of long-term incubations with Adv on the CD34 ϩ positivity of HSCs after manipulation have been reported, these effect may be critical to ensure the pluripotent repopulating potential of the Adv-transduced cells.
Another concern is that these manipulations can cause the CD34 ϩ cells to differentiate into more terminal cell phenotypes, and that these more committed HSCs will not provide the full repertoire of hematopoietic cells. An additional concern with the use of high MOIs on HSCs is the apparent toxicity related to the Adv cytopathological effects. This toxicity was described by Seth et al, 30 who observed a 50% reduction in the formation of GM-CFUs at an MOI of 1000 with Adp53, and in the report by Frey et al, 37 who observed that the transduction of CD34 ϩ cells at an MOI of Ͼ100:1 resulted in a significant reduction in GM-CFU/granulo- ϩ cells by FACS analysis and found only a negligible level (Ͻ5%). We have studied both the CAR and ␣ V ␤ 3 and ␣ V ␤ 5 receptors on CD34 ϩ cells from both BM and peripheral blood stem cells and found them to be expressed on Ͻ3-5% of HSCs (our manuscript submitted for publication). The very low levels of the Adv receptors are one reason why HSCs do not efficiently take up Adv, whereas some solid tumor cells that do express high levels of receptor are transduced more efficiently. At MOIs as high as 500 -1000 pfu/cell and with very long incubation times (24 -48 hours), hematopoietic cells and HSCs are probably transduced via the nonspecific adhesion of Adv to the cell surface followed by internalization via endocytosis or alternatively some undescribed internalization pathways.
To transduce cancer cells in hematological malignancies, Wattel et al 28 used an infection protocol (with Ad␤-gal) that involved an MOI of 200:1 and a 2-hour incubation. They observed the transduction frequency to be high in K562 (a chronic myeloid leukemia (CML) blast crisis cell line, 64%) and RPMI 8226 (a myeloma cell line, 65%) cells and moderate in two other myeloma cell lines (41% in U266, 20% in NCI-H929) and an adult T-cell leukemia cell line (38% in MT4). The transduction efficiency of other hematological cells such as acute myeloid leukemia, T-acute lymphoblastic leukemia cells, and B lymphoma cells was reported as low or absent. Huang et al 18 observed a transduction frequency of 40 -50% in normal monocytes and 50 -80% in primary CML cells by Ad␤-gal with an MOI of 13 when they infected cells in a minimum volume of medium or used a centrifugal procedure (1000 ϫ g; 90 minutes; 32°C). In a recent report, Tosi et al 40 further confirmed the ability of Adv to infect K562 cells and improved the transduction frequency of HL-60 to 51.5% by increasing the infection time to 24 hours with an MOI of 100. These results are in contrast to the 3% transduction frequency of K562 cells reported by Wattel et al, 28 who used the same Adv, but only a 2-hour incubation and an MOI of 200. These results suggest that incubation time is more important than MOI in determining transduction efficiency. It is noteworthy that in other hematological malignancies, such as in myeloid leukemic HL-60 cells, a markedly longer infection time increases the level of transduction, just as it does in normal hematopoietic cells. This increase could result from a nonspecific endocytotic uptake; that is, Adv could be taken up nonspecifically through normal endocytosis or through an unidentified slow infection pathway that may rely on a weakly expressed, undescribed receptor molecule.
Hu et al 41 raise an interesting issue in a recent report. They incubated hematopoietic cells with a tumor necrosis factor encoding Adv at an MOI of 100 for 1 hour, after which the cells were plated. They detected Advdelivered tumor necrosis factor transcripts in 4 of 10 granulopoietic colonies by RT-PCR. Before their study, most of the studies evaluating Adv transduction into HSCs had used either FACS to measure the marker enzyme activity or 5-bromo-4-chloro-3-indolyl ␤-D-galactoside histochemical staining to determine the percentage of expressing cells. Both methods are much less sensitive than RT-PCR. The data of Hu et al 41 suggest that Adv is in fact taken up quickly, possibly through a receptor-mediated event, and that the other methods of detection are insensitive to the low levels of reporter gene activity (or Adv transduction) observed with short incubations.
TROPISM-MODIFIED ADV (Fig I)
Redirecting or retargeting Adv could solve many of the problems that hinder the systemic delivery of Adv vectors in a clinical setting. A detailed review on Adv redirection is provided in Bilbao et al. 42 As noted above, the natural tropism of Adv appears to function in many epithelium-derived cell types. This makes it impossible to control the systemic delivery of Adv in vivo. Designs of cell-type specific recombinant Adv vectors would seem necessary if delivery is to be controllable. For some cell types, such as smooth muscle and hematopoietic cells that express low levels of CAR and/or ␣ V integrin receptors, redirecting Adv to some of the other cell surface receptors on these cells would make it possible to deliver genes to these cell types. For malignancies that overexpress normal receptors or, better, tumor-specific receptors, the retargeting of Adv to these receptors would lead to selective killing of the malignant cells. There are several points to consider, however, when attempting to modify Adv tropism. First, one must consider the natural pathway of attachment and internalization, particularly what protein interactions occur and their consequences. Because it is well known that both fiber and penton base coat proteins are involved in productive infections, either of these two proteins could be modified to directly or indirectly bind to novel cell surface receptors. One must also take into consideration that it is necessary for any event that can trigger internalization through endosomal uptake to occur after attachment.
Michael et al 43 first demonstrated that new cell-type specificities could be achieved with a retargeted Adv fiber. In their study, a gastrin-releasing peptide was introduced onto the carboxyl terminus (fiber knob) of the Adv fiber protein. The resultant fiber-gastrin-releasing peptide fusion protein was then correctly transported to the nucleus of HeLa cells. Wickham et al 44, 45 at the same time developed penton base chimeras that recognized cell-specific integrin molecules or inflammationinduced cellular receptors (E-selectins), and observed efficient retargeting of Adv to endothelial cells in an in vitro system. Krasnykh et al 46 developed a two-plasmid system that generates Adv vectors containing variant fiber molecules capable of cell-specific targeting. Douglas et al 47 targeted the folate receptor, which is overexpressed on the surface of many malignant cells, such as melanoma cells. They conjugated folate to the neutralizing Fab fragment of an antifiber monoclonal antibody. The resultant Fab-folate conjugate was then complexed with an Adv vector and observed to redirect Adv at high frequency via the folate receptor. Other recombinant Adv vectors also have been constructed that can be redirected to target different cell receptors such as heparin sulfate-containing receptors, 23, 48 basic fibroblast growth factor (FGF) receptors on vascular endothelial cells, 45 epidermal growth factor-receptors, which are overexpressed on a variety of neoplasms, 49 and FGF-R2 receptors, which are overexpressed on pancreatic carcinomas. 50 To retarget to those cells that lack CAR receptors but have sufficient expression of ␣ V integrins, linking of the Adv penton base to a cell surface receptor could improve transduction, because internalization would still be initiated once the penton base is able to overcome the steric hindrance imposed by the longer fiber proteins and eventually bind the ␣ V integrins. Modifying Adv to efficiently infect endothelial and smooth muscle cells is an example of this kind of retargeting. In this regard, Wickham et al 51 constructed an Adv, AdFLAG, which has incorporated a FLAG peptide epitope into its penton base. With a bispecific antibody that comprised a monoclonal antibody to FLAG at one end and a monoclonal antibody to ␣ V integrins on the other, Adv was then successful at transducing endothelial and smooth muscle cells. This same approach was used to redirect Adv to T cells via the CD3 receptor. Along another line, von Seggern et al 52 demonstrated successful transduction into hematopoietic cells that lack CAR by using a fiberless Adv. Their work suggests that Adv can attach and internalize in monocytic leukemia cells by a predominantly integrin-mediated pathway, suggesting a bypass of the requirement of CAR-fiber interactions.
RETARGETING ADV TO HEMATOPOIETIC CELLS
Retargeting in many cases could be far more complicated than it theoretically appears. For instance, retargeted Adv binding to a new receptor does not necessarily guarantee transduction because in addition to virus binding, receptor-mediated endocytosis also must take place for a productive infection to occur. Retargeting is unlikely to be successful if the receptor to which the Adv fiber is being redirected does not turn over or does not initiate internalization in the cells that also do not possess enough ␣ V integrins to bind to the viral penton RGD domain.
In addition, retargeting Adv, especially to HSCs and other hematological cells, is still a challenge. This was shown by the work of Tillman et al, 53 who studied the retargeting Adv entry into B lymphocytes via the Epstein-Barr virus (EBV) pathway. They reasoned that because EBV binds to the B-cell surface receptor CD21 and is then followed by internalization into membranebound vesicles, they could chemically conjugate a CD21 antibody to the Fab fragment of a neutralizing antifiber monoclonal antibody by complexing the conjugate with Adv. By doing this, they were able to direct Adv binding specifically to CD21 receptors on B cells. However, subsequent experiments in which this redirected Adv was used showed little gene transfer. This group is currently working on new strategies to trigger internalization and mediate efficient gene transfer. We also have attempted to specifically redirect Adv to CD34
ϩ HSCs via the CD34 receptor with the AdFLAG virus described by Wickham et al. 44 As part of this effort, we have created a bispecific antibody that recognizes both the CD34 receptor and the FLAG epitope that was incorporated into the Adv penton base. Although this bispecific antibody recognized both individual targets, after using the complex of the bispecific antibody conjugate and the AdFLAG virus, specific binding was not followed by successful viral transduction because the reporter gene expression level was no different than the control AdFLAG itself. A possible reason for this failure is that internalization did not occur because HSCs lack the ␣ V integrin molecules. A further contributing factor may be that the CD34 receptor is a protein receptor that is shed and not internalized after triggering. These collective results suggest that the CD34 receptor itself is not an ideal target for redirecting Adv, and that there is a need for better target receptor molecules that can trigger internalization.
A successful method of redirecting Adv to HSCs has been developed by Wickham et al. 23 These investigators created a genetically modified fiber mutant AdvZF(pK7) that has seven lysines incorporated into its fiber end; it binds to any heparin sulfate-containing receptors. This vector does not require CAR for viral attachment and has been shown to be 10 -200 times more efficient at infecting many different cell types that are not typical Adv targets. We have demonstrated efficient transduction of CD34 ϩ cells at a low MOI (50 pfu/cell) and a short incubation time (Ͻ2 hours) (our manuscript submitted for publication). So far, this vector has shown great efficiency in infecting HSCs without the need for long incubation periods or cytokine mixtures. In a recent publication, Pederson et al 50 described an immunologically redirected Adv that also has shown promise in infecting a number of non-Adv target cells, including HSCs and many of the same cell types as the AdvZF(pK7) vector. In their work, they have constructed a single-chain antibody (SFv) to neutralize knob-CAR binding, and they have conjugated it to the b-FGF ligand.
FUTURE DIRECTIONS OF ADV-MEDIATED STEM CELL GENE THERAPY
The demonstration that Adv can transduce HSCs or progenitor cells efficiently may initiate new applications of Adv-mediated gene transfer into HSCs. As stated above, this transduction is possible with higher MOIs, longer incubation times, cytokine stimulation of HSCs, or retargeted viruses. However, all of these methods have alternative effects that may limit their widespread application. Thus, a more efficient vector would be beneficial. The development of Advs to target specific receptors on HSCs would be a reasonable direction to pursue.
A simple bypass of inefficient wild-type Adv transduction into hematopoietic cells has been demonstrated with Adv complexes. Data described by Dietz and VukPavlovic 54 have shown that dendritic cells (DCs) derived from CD34 ϩ cells can be efficiently transduced by Adv complexed with a simple liposomal reagent (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium methylsulfate; Boehringer Mannheim, Indianapolis, Ind). Another report suggests that incubation of DCs with an Adv-polyethylenimine complex also yields high-level transduction of DCs. 55 The creation of a virus-polycation complex with polyamidoamine dendrimers also has resulted in efficient transduction of primitive leukemic and normal CD34 ϩ cells. Interestingly, the complex formation accelerated the transduction kinetics into these hematopoietic cells, resulting in times similar to those observed with wild-type virus-receptor interactions. 56 These virus-charged complexes suggest that techniques designed to maintain close interaction of Adv proteins and hematopoietic cells are critical for efficient transduction in the absence of typical viral receptor proteins. 57 Another alternative is the use of hybrid vector systems that possess multiple vector types (i.e., retroviral vectors and Adv vectors). Such hybrid systems combine an Adv that is capable of highly efficient infection with retroviral 58 and adenoviral adeno-associated virus systems, 59 which have long-term integrating potential. A two-vector Adv system has been created that contains the gag-polenv trans-acting functions on one virus and the gene-ofinterest vector possessing the retroviral long terminal repeats, the packaging site, and other cis-acting sequences on the other. 60, 61 After coinfection of both Advs, the recipient cell becomes a transient retroviral producer cell and spreads a high-titer retroviral vector to neighboring cells. It is unclear, however, whether the recipient cells that become the transient package also maintain the integrated provirus. This vector system has many potential applications.
Another recently created hybrid virus contains actively replicating episomal vectors, with the origin of replication coming from EBV. 62 After infection into a target cell, both of these vector systems produce the required EBV nuclear antigen proteins for episomal maintenance, as well as the gene-of-interest episomal vector. It has been shown that this episome is maintained in the long-term in vitro system of the subsequent daughter cells, but it has not been tested in an in vivo system, in which episomal vectors tend to be lost. This hybrid vector is another possible means of obtaining long-term expression from an Adv system.
In a recent report that also considers long-term expression from an Adv system, Zeng et al 63 observed that Adv genes were integrated into host cells after the transduced cells were irradiated. This combination of retargeted Adv vectors followed by the delivery of ionizing radiation to the HSCs could therefore constitute another means of achieving long-term expression of the desired genes.
CONCLUSIONS
The potential application of gene transfer to hematopoietic cells has increased because it has become apparent that Adv does infect HSCs by certain protocols. However, although the use of high MOIs and long incubation times ensures some transduction to HSCs, this transduction is accomplished at the possible expense of the repopulating potential. It appears that the application of a cytokine mixture also can increase the transduction potential, but a drawback is that the pluripotent stem cells may no longer be pluripotent, but rather differentiated. Conversely, lower MOIs and short incubation periods have proved beneficial for the removal of contaminating cells in HSC grafts. Therefore, it appears that transduction conditions can be manipulated to achieve either efficient infection or little transduction. There are, however, many unresolved questions as to how Adv transduces HSCs. Although the data suggest a slow, nonspecific uptake pathway, there is a possibility that an undescribed, fast receptor-mediated uptake is operational.
One possible way to not endanger the pluripotentiality and ensure the efficient transfer of genes to HSCs is to use retargeted or genetically modified Advs. The use of retargeted Advs also may enable systemic administration, currently the goal of researchers working on the development of gene therapy protocols. Genetically modified Advs also may become more capable of infecting new target cells, such as HSCs. The development of these viruses will likely spawn new clinical applications of Adv gene transfer to HSCs and other hematopoietic cells. For example, the expression of cytokine genes and/or costimulatory genes in CML or acute myeloid leukemia blast cells may be used to create immunovaccines for residual leukemias. A further possibility is the expression of cytokine genes in HSCs to prevent unwanted differentiation during transplantation or to prevent tumor cell establishment in BM. They may even be used to accomplish the expression of anti-apoptotic genes in HSCs to prevent cell death during cryopreservation or to induce apoptosis in selected leukemic cell populations. The future is very promising for this new technology, and as better vectors are created, the holy grail of gene therapy, the specifically targeted injectable vector, may be achieved.
